Results 181 to 190 of about 6,419 (213)

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis

Annals of Medicine, 2022
Feng Zhanhui, Mingwei W
exaly  

Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study

The Lancet Regional Health - Western Pacific, 2023
dechang chen
exaly  

Paxlovid Prescribing Requires Pharmacy Workload Assessments

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

Paxlovid (nirmatrelvir/ritonavir).

WMJ : official publication of the State Medical Society of Wisconsin, 2022
Kristin, Busse, Abir T, El-Alfy
openaire   +1 more source

Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: A rapid review and meta‐analysis

Journal of Medical Virology, 2023
Behnam Amani, Bahman Amani
exaly  

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?

Biomedicine and Pharmacotherapy, 2023
AMIRHOSSEIN SHEIDA, Hossein Bannazadeh Baghi, Michael R. Hamblin   +2 more
exaly  

A Television Interview with Paxlovid

Daxue Huaxue, 2022
Minghong Yang, Hongjian Lu, Zhen Shen, Kin Shing Chan   +3 more
openaire   +1 more source

Dosing errors common with Paxlovid

Reactions Weekly, 2022
openaire   +1 more source

Genetic Surveillance of SARS-CoV-2 M pro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid

MBio, 2022
Jonathan T. Lee, Qingyi Yang, B. Scott Perrin, Jr.   +2 more
exaly  

PAXLOVID-ASSOCIATED STEVENS-JOHNSON SYNDROME

CHEST, 2023
MONICA MALVIYA, SHANAN BARUA, MANGALORE AMITH SHENOY, ATEEQA MUJEEB ULLAH   +3 more
openaire   +1 more source